Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 118.94M shares rose 27.4% year over year, behind the +29.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +27.4% toward the trailing-twelve-month pace of +29.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
118.94M+7.0% QoQ
Last fiscal yearDec 2025
94.57M+38.8% YoY
LTMSep 2026
108.82M+29.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.4%——
1 year+38.8%——
3-year CAGR+12.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
94.57M USD
Year-over-year change
+38.8%
4-year CAGR
+13.1%

Weighted Avg Shares (Diluted) vs competitors

How AMLX compares with its peers on the latest reported figures

  • AMLX's LTM Sep 2026 weighted avg shares (diluted) of 108.82M shares is the 3rd highest of the 10 companies compared; the peer median is 85.54M shares.
  • Its year-over-year change of +29.3% is the 5th highest of 10, against a peer median of +5.8%.
  • Over three fiscal years its annual growth of +12.4% compares with a peer median of +11.8%.
AMLX Competitors Peer median
Weighted Avg Shares (Diluted) for AMLX and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026108.82M +29.3%+12.4%
ACIUAC Immune S.A.LTM Mar 202699.9M -0.5%+6.4%
AVXLAnavex Life Sciences Corp.LTM Dec 202586.34M +2.9%+3.5%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +45.8%+78.9%
PRTAProthena Corporation plcLTM Mar 202653.9M -0.4%+4.4%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
PMNProMIS Neurosciences, Inc.LTM Jun 20264.71M +249.6%+80.2%
Peer median (excluding AMLX) 85.54M+5.8%+11.8%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue022.23M380.79M87.37M0
Cost of Revenue02.99M25.44M42.16M525K
Gross Profit019.24M355.35M45.22M(525K)
Gross Margin—86.5%93.3%51.8%—
Research & Development44.04M93.45M128.19M104.08M90.4M
Selling, General & Admin38.93M127.13M188.36M114.33M62.89M
Operating Expenses82.69M220.58M316.54M359.95M152.77M
Depreciation & Amortization52K487K1.09M904K525K
EBITDA(87.88M)(197.11M)55.39M(290.98M)(144.16M)
EBITDA Margin—-886.7%14.5%-333.0%—
Operating Income(82.69M)(201.34M)38.8M(314.73M)(153.29M)
Operating Margin—-905.7%10.2%-360.2%—
Interest Income36K4.29M16.16M13.81M9.3M
Interest Expense00000
Other Income / Expenses(5.24M)3.74M15.5M12.6M8.6M
Income Before Tax(87.93M)(197.6M)54.3M(302.14M)(144.69M)
Pre-Tax Margin—-888.9%14.3%-345.8%—
Income Tax Expense0774K5.03M(393K)46K
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Net Margin—-892.4%12.9%-345.4%—
EPS (Basic)(1.52)(2.98)0.73(4.43)(1.53)
EPS (Diluted)(1.52)(2.98)0.70(4.43)(1.53)
Weighted Avg Shares57.86M66.51M67.23M68.14M94.57M
Weighted Avg Shares (Diluted)57.86M66.51M69.99M68.14M94.57M

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.